delavirdine has been researched along with AIDS Seroconversion in 4 studies
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Delavirdine is a potent and reversible inhibitor of hepatic CYP3A; it is also a substrate for this CYP450 isoform." | 2.68 | Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. ( Amidon, GL; Blake, DS; Carver, PL; Cheng, CL; Cox, SR; Kauffman, CA; Meyer, KM; Smith, DE; Stetson, PL; Watkins, PB, 1997) |
| " On day 30, statistically significant differences between groups were observed for all delavirdine pharmacokinetic parameters (p < 0." | 2.68 | Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ( Borin, MT; Carel, BJ; Chambers, JH; Freimuth, WW; Gagnon, S, 1997) |
| "16) in delavirdine pharmacokinetic parameters between treatment groups on day 15 or day 30." | 2.68 | Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. ( Anderson, RD; Borin, MT; Carel, BJ; Cox, SR; Freimuth, WW; Herman, BD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, CL | 1 |
| Smith, DE | 1 |
| Carver, PL | 1 |
| Cox, SR | 2 |
| Watkins, PB | 1 |
| Blake, DS | 1 |
| Kauffman, CA | 1 |
| Meyer, KM | 1 |
| Amidon, GL | 1 |
| Stetson, PL | 1 |
| Borin, MT | 2 |
| Chambers, JH | 1 |
| Carel, BJ | 2 |
| Gagnon, S | 1 |
| Freimuth, WW | 2 |
| Herman, BD | 1 |
| Anderson, RD | 1 |
| Shelton, MJ | 1 |
| Akbari, B | 1 |
| Hewitt, RG | 1 |
| Adams, JM | 1 |
| Morse, GD | 1 |
3 trials available for delavirdine and AIDS Seroconversion
| Article | Year |
|---|---|
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
Topics: Administration, Oral; Adult; Alkylation; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Breath Test | 1997 |
Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
Topics: Adult; Alkylation; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Blot | 1997 |
Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cy | 1997 |
1 other study available for delavirdine and AIDS Seroconversion
| Article | Year |
|---|---|
Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients.
Topics: Achlorhydria; Adult; Anti-HIV Agents; Delavirdine; Helicobacter Infections; Helicobacter pylori; HIV | 2000 |